Free Newsletter
SPOTLIGHT: FDA panel votes to restrict Ketek
An FDA advisory panel has voted to restrict the use of Sanofi-Aventis' controversial antibiotic Ketek. Panel members said that the risks outweighed the benefits of using Ketek against acute bacterial sinusitis and acute bacterial exacerbation of chronic bronchitis. Report






Click here to get the FierceBiotech email newsletter for FREE!
Be the first to comment